close

Agreements

1 201 202 203 204 205 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2013-03-07 AstraZeneca (UK) Cancer Research Technology (CRT) (UK) drugs targeting cancer metabolism

R&D

Cancer - Oncology R&D agreement
2013-03-06 Servier (France) Galapagos (Belgium) research - R&D - development - commercialisation Cancer - Oncology Milestone
2013-03-06 Roche (Switzerland) BioLamina (Sweden) laminin-based in-vitro cell culture matrices

R&D

Regenerative medicine R&D agreement
2013-03-06 Grunenthal (Germany) Ethypharm (France) fentanyl sublingual tablets cancer pain

licensing
commercialisation
distribution
supply

Cancer - Oncology - CNS diseases Licensing agreement
2013-03-05 DBV Technologies (France) Sanofi (France) Active Pharmaceutical Ingredients (API)

production
manufacturing

Allergic diseases - Immune diseases Production agreement
2013-03-05 Riboxx Pharmaceuticals (Germany) China National Biotec Group Company Limited (CNBG - China) Riboxxim® undisclosed

R&D

Infectious diseases R&D agreement
2013-03-05 AstraZeneca (UK) Targacept (USA) alpha7 NNR modulators, alpha4beta2 NNR modulators including AZD1446 and TC-1734 cognitive disorders, schizophrenia, Alzheimer’s disease

development
licensing
commercialisation

CNS diseases - Mental diseases - Psychiatric diseases - Neurodegenerative diseases Development agreement
2013-03-05 PSR Orphan Experts (The Netherlands) Agility Clinical (USA) consulting, orphan drug development services

collaboration

Rare diseases Collaboration agreement
2013-03-04 Addex Therapeutics (Switzerland) Viva Biotech (China) oral small molecule adenosine 2A receptor (A2AR) positive allosteric modulators (PAMs)

R&D

Rare diseases - Inflammatory diseases R&D agreement
2013-03-01 TikoMed (Sweden) Baylor Research Institute (USA) IBsolvMIR chronic pancreatitis patients receiving islet transplantation

clinical research

Transplantation - Metabolic diseases Clinical research agreement
2013-02-28 BioAlliance Pharma (France) undisclosed worldwide leader in vaccines Lauriad® mucoadhesive technology

collaboration

Infectious diseases Collaboration agreement
2013-02-26 Oxford Gene Technology (UK) Cancer Cytogenomics Microarray Consortium (CCMC) (UK) whole genome, cancer-specific microarray.

licensing

Cancer - Oncology Licensing agreement
2013-02-26 Xellia Pharmaceuticals (Norway) SINTEF Materials and Chemistry (Trondheim) the Statens Serum Institut (Denmark) new antibiotics that target Gram-negative bacterial infections Gram-negative bacterial infections R&D Infectious diseases
2013-02-26 Jazz Pharmaceuticals (Ireland) Concert Pharmaceuticals (USA - MA) deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323

development

licensing

commercialisation

CNS diseases Licensing agreement
2013-02-25 Ablynx (Belgium) Spirogen (UK) anti-cancer drug conjugate combining Spirogen\'s proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx\'s proprietary technology platform

R&D

Cancer - Oncology R&D agreement
2013-02-25 Xellia Pharmaceuticals (Norway) SINTEF Materials and Chemistry (Denmark) the Statens Serum Institut (Denmark) new antibiotics multi-drug resistant (MDR), Gram-negative bacteria infections Infectious diseases
2013-02-25 Bone Therapeutics (Belgium)

construction of a production plant

Construction of a production plant
2013-02-22 IntegraGen (France) Lab21 (UK) microRNA assay for colorectal cancer diagnostic (detection of a biomarker called hsa-mir-31-3p) colorectal cancer R&D Cancer - Oncology
2013-02-21 UCB (Belgium) ConfometRx (USA) novel medicines addressing unmet medical needs in Neuroscience and based on G-protein coupled receptor (GPCR) modulation R&D
2013-02-20 Cangene (Canada) Ipsen (France) Inspiration Biopharmaceuticals (USA) IB1001 and certain other assets including two product candidates in pre-clinical development, IB1007 (a recombinant FVIIa) and IB1008 (a recombinant FVIII). hemophilia B asset purchase
acquisition
Genetic diseases - Hematological diseases